RedHill Biopharma releases corporate presentation outlining Talicia commercialization, late-stage pipeline progress
Reuters2026/08/03 07:00- RedHill Biopharma outlined its U.S. specialty pharma strategy focused on GI diseases, infectious diseases, oncology, led by Talicia commercialization.
- FY 2025 net revenue USD 7.8 million; cash balance USD 4.1 million; gross margin 74.6%.
- Equity financing capacity USD 31.7 million via an at-the-market purchase agreement, backed by a SEPA facility.
- Talicia positioned as the leading branded H. pylori prescription among U.S. gastroenterologists; U.S. patent protection through 2042; QIDP exclusivity through 2027.
- Pipeline priorities include opaganib in a Phase 2 combination study with Bayer’s darolutamide in prostate cancer, backed by multiple late-stage programs.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Geopolitical tensions overshadowing production cuts: OPEC+ maintains quotas unchanged, paper adjustments fail to resolve physical supply dilemmas
OPEC+ major oil producers, led by Saudi Arabia and Russia, held a monthly video conference last Sunday and decided to keep the crude oil production quota for October unchanged, continuing the previous tone of stable production following a series of symbolic production increases.
No Public Money Behind El Salvador’s New Bitcoin, IMF Confirms
PetroTal forecasts FY2026 adjusted EBITDA at USD 110 million-120 million
2-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
